Personalized treatment in metastatic triple‐negative breast cancer: The outlook in 2020-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Personalized treatment in metastatic triple‐negative breast cancer: The outlook in 2020

Published:2019-12-23 Issue:1 Volume:26 Page:69-80
ISSN:1075-122X
Container-title:The Breast Journal
language:en
Short-container-title:Breast J

Author:

Azim Hamdy A.¹²,Ghosn Marwan³,Oualla Karima⁴,Kassem Loay¹²

Affiliation:

1. Clinical Oncology Department Kasr Alainy School of Medicine Cairo University Giza Egypt

2. Clinical Oncology Department Cairo Oncology Center Cairo Egypt

3. Hotel Dieu de France University Hospital and Saint Joseph University Beirut Lebanon

4. Medical Oncology Department Hassan II University Hospital Fes Morocco

Publisher

Hindawi Limited

Subject

Oncology,Surgery,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/tbj.13713

Reference85 articles.

1. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

2. Potential Therapeutic Targets in Triple Negative Breast Cancer

3. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

4. Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design

5. VEGF, HIF-1α Expression and MVD as an Angiogenic Network in Familial Breast Cancer

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antitumoral and Antimetastatic Activity by Mixed Chelate Copper(II) Compounds (Casiopeínas®) on Triple-Negative Breast Cancer, In Vitro and In Vivo Models;International Journal of Molecular Sciences;2024-08-13

2. Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro;International Journal of Molecular Sciences;2024-03-06

3. Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response;Exploration of Targeted Anti-tumor Therapy;2024-02-28

4. Nano-Based Drug Delivery of Anticancer Chemotherapeutic Drugs Targeting Breast Cancer;Recent Patents on Anti-Cancer Drug Discovery;2023-08

5. HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review;Current Oncology;2023-06-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3